ICCM Stock Analysis: Buy, Sell, or Hold?
ICCM - IceCure Medical Ltd. Ordinary Shares
$2.21
0.07 (3.27%)
▲
5d:
+0.45%
30d:
-28.82%
90d:
-17.54%
HOLD
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When ICCM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ICCM shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ICCM shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: ICCM is currently trading at $2.21, which is considered slightly low relative to its 30-day fair value range of $2.17 to $3.01. From a valuation perspective, the stock is trading at a discount (Forward PE: -0.6) compared to its historical average (7.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ICCM is in a uptrend. Immediate support is located at $2.06, while resistance sits at $2.50. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: ICCM scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $22.67 (+925.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ICCM is in a uptrend. Immediate support is located at $2.06, while resistance sits at $2.50. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: ICCM scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $22.67 (+925.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.17 -
$3.01
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
100.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (70/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.3%)
- BULLISH: Trading 925.6% below Wall St target ($22.67)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Bottoming setup, but lagging the sector by 23% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$2.17 -
$3.01
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.06
Resistance Level
$2.50
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.64
Wall Street Target
$22.67
(+925.6%)
Revenue Growth (YoY)
72.8%
PE vs Historical
-0.6 vs 7.5
CHEAP
Share & Embed Analysis
Last updated: September 12, 2026 11:09 PM ET
Data refreshes hourly during market hours. Next update: 12:09 AM
Data refreshes hourly during market hours. Next update: 12:09 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ICCM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 56 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 41 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 41 HOLD |
